Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

160 results about "Renal tissue" patented technology

A thin layer of fibrous connective tissue forms the renal capsule surrounding each kidney. The renal capsule provides a stiff outer shell to maintain the shape of the soft inner tissues. Deep to the renal capsule is the soft, dense, vascular renal cortex.

Clear cell renal cell carcinoma biomarkers

Disclosed herein is a clear cell renal cell carcinoma (ccRCC) biomarker set. Also disclosed herein is a detection system using the biomarker set disclosed herein, methods of determining whether a subject has or shows recurrence of clear cell renal cell carcinoma, method of determining whether a renal mass sample is benign or malignant, method of detecting response of a subject to systemic treatment, and a kit for carrying out the same.
Owner:AGENCY FOR SCI TECH & RES +1

Preparation and application of combined subunit vaccine for hemorrhagic disease and septicemia of grass carp

The invention discloses preparation and application of a combined subunit vaccine for hemorrhagic disease and septicemia of grass carp. The invention provides a fusion gene obtained by connecting VP6 protein of GCRV and ompAII protein of aeromonas veronii, the fusion gene expresses fusion protein and is combined with an adjuvant to construct a biunit vaccine for intraperitoneal injection immunization of an experimental animal, spleen and kidney tissues are collected, and the expression level of immune related genes in each tissue is measured; results show that the prepared bivalent subunit vaccine can stimulate different immune tissues of a fish body to generate immune response reaction through injection immunization; gCRV virulent virus and aeromonas veronii are injected into the abdominal cavity for a fish body challenge experiment on the 28th day after immunization, and the relative survival rates of aeromonas veronii and grass carp reovirus infection are 85% and 55% respectively 15 days after challenge, so that the bivalent subunit vaccine disclosed by the invention has a relatively good protection effect on important diseases of cultured grass carp.
Owner:PEARL RIVER FISHERY RES INST CHINESE ACAD OF FISHERY SCI

Application of oligopeptide in preparation of medicine for treating and / or preventing diabetic nephropathy

The invention discloses application of oligopeptide in preparation of a medicine for treating and / or preventing diabetic nephropathy. The oligopeptides comprise oligopeptides with the amino acid sequence of SEQ ID NO: 1: LNLYP and derivative sequences or conservative substitution variants of the oligopeptides. The oligopeptide can significantly improve renal function indexes of mice with diabetic nephropathy, such as UACR, serum creatinine, urea nitrogen and the like, enhance podocyte barrier integrity and inhibit accumulation of advanced glycosylation end products AGEs in kidney tissues, and provides a basis for development of novel drugs for treating diabetic nephropathy.
Owner:CHINA PHARM UNIV

Application of substance taking SAA2 gene as target spot in preparation of kit for diagnosing DKD and medicine for treating DKD

The invention discloses application of a substance taking an SAA2 gene as a target spot in preparation of a kit for diagnosing DKD and a medicine for treating DKD, relates to the technical field of detection of gene target spots related to diabetic nephropathy and research and development of targeted medicines, discloses an effect of the SAA2 gene in diagnosis of DKD, and meanwhile, finds that expression of the SAA2 gene in DKD kidney tissues is increased, and the expression of the SAA2 gene in the DKD kidney tissues is reduced. The result is negatively correlated with renal function. The invention also finds that the SAA2 gene is related to podocyte injury and inflammatory response, and can reflect the inflammation level of DKD to a certain extent. The effect of the compound in DKD-mediated inflammatory reaction can be verified through further in-vivo and in-vitro experiments subsequently, and a certain theoretical basis is laid for research and development of targeted drugs.
Owner:SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG PROVINCIAL HOSPITAL)

Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof

The invention relates to a traditional Chinese medicine composition for treating diabetic nephropathy and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine compositions. In order to solve the problems that the target spot of western medicine for treating diabetic nephropathy is single, and the adverse reaction risk is large when multiple medicines are combined for use, the invention provides a traditional Chinese medicine composition for treating diabetic nephropathy, and the traditional Chinese medicine composition comprises white ginseng, astragalus membranaceus, scorched atractylodes macrocephala, poria cocos, endothelium corneum gigeriae galli, kudzu vine root, medlar, Chinese yam, dogwood and rhizoma alismatis. The traditional Chinese medicine composition has the advantages of multiple components, multiple targets and small adverse reaction, animal experiments prove that the traditional Chinese medicine composition provided by the invention can remarkably improve the levels of blood sugar, blood fat, urine protein, creatinine and urea nitrogen of rats, can remarkably improve pathological changes of renal tissues of model rats, can specifically increase the activity of SIRT1 and PGC-1alpha, and can be used for treating the renal diseases of the rats. The traditional Chinese medicine composition can be used for treating diabetic nephropathy, correcting the metabolic pathway of podocyte and recovering the mitochondrial function, is an effective medicament for treating diabetic nephropathy, and provides a new pathway for clinical multi-target treatment of diabetic nephropathy.
Owner:HEILONGJIANG UNIV OF CHINESE MEDICINE

Leixihaokang, preparation method therefor, and use thereof

The present invention belongs to the field of traditional Chinese medicines, and particularly relates to Leixihaokang, a preparation method therefor, and use thereof. The Leixihaokang of the present invention is prepared from the following active pharmaceutical ingredients in parts by weight: 10 parts of Tripterygium glycosides and 0.1-1.3 parts of Artemisia annua extract. According to the present invention, animal experiments prove that the Leixihaokang can ameliorate renal damage in nephrotic syndrome caused by adriamycin, reduce the occurrence of proteinuria, and reduce the apoptosis of renal tissue cells. Meanwhile, the Leixihaokang of the present invention has a good inhibitory effect on renal, hepatic, splenic, and cardiac toxicity in the treatment process of nephrotic syndrome. According to the present invention, animal experiments also prove that the Leixihaokang can ameliorate skin injury in imiquimod-induced psoriasis, reduce inflammatory infiltration and alleviate skin damage. Meanwhile, the Leixihaokang has a certain degree of inhibitory effect on the hepatic and reproductive system toxicity in the treatment process of psoriasis.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE +2

Application of AQP1 in preparation of diagnostic reagent and therapeutic drug for hypoglucose tolerance nephropathy

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.
Owner:ZHU XIANYI MEMORIAL HOSPITAL OF TIANJIN MEDICAL UNIV (TIANJIN MEDICAL UNIV METABOLIC DISEASE HOSPITAL TIANJIN METABOLIC DISEASE PREVENTION CENT) +1

Biomarker for detecting kidney fibrosis related diseases and application thereof

The invention belongs to the technical field of medicines, and particularly discloses a biomarker for detecting kidney fibrosis related diseases and application of the biomarker. The biomarker comprises serum copper cyanin, or the serum copper cyanin and serum creatinine. Compared with other methods for diagnosing renal fibrosis, the serum cupreuloplasmin has the following three advantages: 1, compared with a conventional diagnostic marker (such as serum creatinine), the cupreuloplasmin can detect up-regulation in the serum of a patient suffering from early chronic kidney diseases, and can be combined with an existing mature diagnostic marker for detection; secondly, compared with renal tissue pathologic biopsy, the use of the copper cyanin as the diagnostic marker has non-invasiveness, and only a small amount or even a trace amount of patient serum is needed, so that the harm to the body health of the patient is avoided; and thirdly, compared with a nuclear magnetic resonance method for analyzing the metabolic components of the urine, the method for detecting the markers in the serum is lower in cost, more flexible, high in timeliness and easier to popularize.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Methods and systems for ablation of the renal pelvis

Apparatus, systems, and methods provide access to the renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances to ablate a thin layer of tissue lining at least a portion of the renal pelvis to disrupt renal nerves within the tissue lining of the renal pelvis.
Owner:VERVE MEDICAL

Multi-lineage human kidney organ in-vitro fusion technology and application thereof

The invention belongs to the technical field of biological medicine, and particularly relates to an in-vitro fusion technology for multi-lineage human kidney organs and application thereof. The invention provides a method for realizing culture of multilineage kidney organs by fusing kidney units and ureteral bud organs in vitro. According to the in-vitro fusion technology of the kidney organoid reported by the invention, two organoid with different pedigree sources, namely the kidney unit and the ureteral bud, can be efficiently fused, a UB tubular structure is integrated into the kidney unit organoid, and the UB tubular structure starts from a single ureteral bud and is wrapped by kidney unit precursor cells in a similar in-vivo development process, and finally develops into a kidney with glomerulus and a plurality of kidney cells. The multi-lineage renal organ comprises a catheter, a proximal tube, a marrow tab thin section, a distal tube, a connecting tube and a ureteral bud with a single outlet. A framework is provided for an engineered renal unit and a smooth collection system, and the method is an important step for generating the functional renal tissue from the beginning.
Owner:GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES

Marker for determining severity of igan renal tissue lesions and use thereof

The application discloses a marker for determining the severity of IgAN kidney tissue lesions and application thereof, and inventors find that ACTN4, ACADS and COL1A1 are significantly differentially expressed proteins in kidney tissues. The significant down-regulation of ACTN4 may cause the change of actin cytoskeleton of IgAN glomerular podocytes; the significant down-regulation of ACAD may indirectly participate in the occurrence process of abnormal structure and function of IgAN renal tubular epithelial cells by affecting fatty acid metabolism in the cells; and the significant up-regulation of COL1A1 may participate in the accumulation of extracellular matrix in the renal interstitium of IgAN, and play a certain role in promoting the renal interstitial fibrosis. The combination of ACTN4, ACADS and COL1A1 has good prediction efficiency for the diagnosis of the severity of IgAN kidney tissue lesions, and the area under the ROC curve is 0.815, P 0.043. In addition, the immunohistochemical results also confirm the expression trend of the three proteins ACTN4, ACADS and COL1A1 in the corresponding kidney tissue substructures in proteomics.
Owner:THE 924TH HOSPITAL OF THE CHINESE PEOPLES LIBERATION ARMY JOINT LOGISTICS SUPPORT FORCE +1

Application of dehydrounionine in the preparation of drugs that reduce polymyxin toxicity

This invention provides the application of dehydrouncitonin in the preparation of drugs that reduce polymyxin toxicity, belonging to the field of pharmaceutical technology. This invention uses dehydrouncitonin in combination with polymyxin. The combined use of dehydrouncitonin and polymyxin E increased the viability of HEK293T and RAW264.7 cells to 87.7% and 94.3%, respectively, with highly significant differences compared to the control, indicating that treatment with dehydrouncitonin in combination with polymyxin E can significantly inhibit the cytotoxic effect of polymyxin E. This invention uses a mouse model to demonstrate that treatment with dehydrouncitonin in combination with polymyxin E can significantly reduce the neurotoxicity and nephrotoxicity of polymyxin E alone in mice, specifically manifested in improved neurobehavioral effects and improved histopathological effects on brain and kidney tissues. This invention uses dehydrouncitonin in combination with polymyxin E to significantly inhibit the cytotoxic, neurotoxic, and nephrotoxic effects of polymyxin E.
Owner:CHINA AGRI UNIV

Application of elsholtzia rugulosa extract in preparation of medicine for preventing and treating acute kidney injury

The invention discloses a novel application of elsholtzia rugulosa extract in preparation of a medicine for preventing and treating acute kidney injury, and belongs to the technical field of biology. The medicine is applied to prevention and / or treatment of acute kidney injury, the content of urea nitrogen (BUN) in plasma can be reduced, pathological injury of kidney tissue is improved, and expression of related factors in the kidney tissue is adjusted; the elsholtzia rugulosa extract can effectively reduce the content of BUN in plasma of a cis-platinum (CDDP)-induced acute kidney injury model mouse, effectively improve pathological injury of kidney tissue of the cis-platinum-induced acute kidney injury model mouse and regulate expression of related factors in the kidney tissue of the cis-platinum-induced acute kidney injury model mouse under a relatively low dosage. The raw materials come from natural products and are convenient to collect and high in safety.
Owner:KUNMING UNIV OF SCI & TECH

The application of the drug for preventing and treating deafness in the preparation of drugs for preventing and treating acute kidney injury caused by cisplatin

The application relates to an application of a drug for preventing and treating deafness in preparation of a drug for preventing and treating acute kidney injury caused by cisplatin, wherein the effective component of the drug for preventing and treating acute kidney injury caused by cisplatin is prepared from raw medicinal materials in the following weight percentage: 27-33% of ginseng, 16-20% of astragalus, 16-20% of pueraria, 11-13% of curcuma, 12-15% of platycodon, and 8-10% of licorice. The drug for preventing and treating acute kidney injury caused by cisplatin in the application can obviously reduce the creatinine and urea nitrogen levels, improve the morphological damage of kidney tissues, and has a remarkable effect on preventing and treating acute kidney injury caused by cisplatin.
Owner:GUANGDONG PHARMA UNIV

Traditional Chinese medicine composition for treating chronic renal failure of pets as well as lipidosome and application of traditional Chinese medicine composition

The invention belongs to the technical field of biological medicines, and particularly relates to a traditional Chinese medicine composition for treating chronic renal failure of pets and a liposome and application thereof. According to the traditional Chinese medicine composition provided by the invention, by virtue of turmeric, eucommia ulmoides, medlar, astragalus membranaceus, poria cocos and beta-sitosterol, the aim of synergistically treating the renal failure in the aspects of resisting inflammation, inhibiting renal fibrosis, improving a glomerular filtration function, promoting kidney cell repair and the like can be achieved, and a new solution is provided for effectively treating the chronic renal failure of pets. The traditional Chinese medicine composition disclosed by the invention has a good recovery effect on kidney tissues of pets with chronic renal failure, can effectively reduce urea nitrogen and creatinine levels of blood of the pets with chronic renal failure, relieves renal failure symptoms, and has a good treatment effect; the liposome disclosed by the invention has the advantages of high effective rate, high cure rate and quick effect, and the treatment effect of the liposome is superior to that of a third-stage clinical medicine, namely beraprost, for treating the kidney renal failure of pets in the current market.
Owner:唐宇翔

Application of PARP1 PROTAC A19 in preparation of medicine for preventing and treating acute kidney injury

The invention discloses an application of PARP1PROTACA19 in preparation of a medicine for preventing and treating acute kidney injury, and relates to the technical field of medicines, and the key points of the technical scheme are as follows: PARP1PROTAC A19 can reduce the expression level of PARP1 in HK2 cells and mice, reduce the levels of acute kidney injury markers KIM-1 and inflammatory factors of the HK2 cells and the mice, improve pathological changes of kidney tissues, and inhibit the occurrence of acute kidney injury. The traditional Chinese medicine composition has obvious prevention and treatment effects on acute kidney injury.
Owner:ANHUI MEDICAL UNIV

Construction method of inducible mouse cystic nephropathy model

PendingCN119054651ATransferasesAnimal husbandryDiseaseGGPS1
The invention provides a construction method of an inducible mouse cystic nephropathy model, which comprises the following steps: inserting an LoxP sequence into two ends of a mouse GGPS1 gene to obtain an LoxP-flox-GGPS1 mouse, introducing CreERT2 recombinase, and under the induction of tamoxifen, specifically knocking out the GGPS1 gene to obtain the model. A plurality of cystic dilated renal tubules appear in kidney tissues of the mouse model in the third week after drug induction, renal cysts start to be formed in the seventh week, meanwhile, the conditions of serum creatinine and urea nitrogen increase occur, the conditions conform to the symptoms and the pathological process of the human cystic nephropathy, and the mouse model can be used for researching the occurrence and development mechanism of the cystic nephropathy and has a good application prospect. The invention also relates to development of drugs for treating the diseases.
Owner:SIR RUN RUN HOSPITAL NANJING MEDICAL UNIV

Traditional Chinese medicine composition and application

The invention provides a traditional Chinese medicine composition and application, and relates to the technical field of medical biologica.In the embodiment of the invention, the treatment effect of the traditional Chinese medicine composition comprising radix astragali, radix et rhizoma rhei, leech, radix salviae miltiorrhizae and herba epimedii on DN model rats is studied through transcriptome sequencing. The rat models are divided into a control group, a DN group and a treatment group. Creatinine (Cr), blood urea nitrogen (BUN), and urinary albumin levels of each group are measured. And the pathological change of the kidney tissue is observed by adopting Masson dyeing and PAS dyeing. The result shows that compared with the DN group, the Cr, BUN and urinary albumin levels of the treatment group are obviously reduced (plt; 0.05) of the method. And the masson dyeing shows that the kidney collagen fibers in the treatment group are reduced. In addition, PAS staining shows that the mesangial expansion of the treatment group is less, and the extracellular matrix deposition is reduced. It is indicated that the composition can effectively reduce the Cr, BUN and urinary albumin levels of DN rats, and has a certain degree of kidney protection effect.
Owner:SICHUAN TAIKANG HOSPITAL CO LTD

Diabetic nephropathy marker PARP1, primer combination and application

The invention discloses a diabetic nephropathy marker PARP1, a primer combination and application, and relates to the technical field of biology. The sequence of the primer combination is PARP1-F, and is as shown in SEQ ID NO. 1; 1, PARP1-R as shown in SEQ ID NO. 2; an internal reference primer beta-actin-F, which is as shown in SEQ ID NO. 17; an internal reference primer beta-actin-R is as shown in SEQ ID NO. 18. The invention finds that the expression of PARP1 in the kidney tissue of a patient with diabetic nephropathy is increased and is positively correlated with ACR (Activated Receptor). The invention also finds that PARP1 is related to podocyte damage, and knocking down PARP1 can relieve podocyte endoplasmic reticulum stress and apoptosis, and can reflect the progress of DKD to a certain extent.
Owner:SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG PROVINCIAL HOSPITAL)

Biomarkers for diagnosing diabetic nephropathy and use thereof

The application discloses a biomarker for diagnosing diabetic nephropathy and application thereof, and relates to the technical field of biological medicine. The biomarker for diagnosing diabetic nephropathy comprises urine MBP-1 or urine MBP-1 / urine creatinine. The urine MBP-1 or urine MBP-1 / urine creatinine biomarker has high identification efficiency: when the urine MBP-1 or urine MBP-1 / urine creatinine ratio is used for identifying DKD and NDRD, the area under the ROC curve (AUC) reaches 0.899, the sensitivity and the specificity are both higher than 0.85, and the two diseases can be efficiently distinguished. The method is non-invasive and convenient: only urine samples need to be collected, the risk of complications such as bleeding and infection caused by invasive operations such as kidney biopsy is avoided, the patient has high acceptance, repeated detection can be performed to dynamically track the disease condition, and special equipment is not needed, so that the method is convenient for clinical popularization and application. Through kidney tissue immunofluorescence verification, MBP-1 is deposited in a large amount in the glomerulus of DKD and is not deposited in NDRD, and thus the kidney local pathological change can be directly reflected.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Lactic acid bacteria strain composition for improving chronic kidney disease and its application

The present invention belongs to the technical field of microbial preparations, and is particularly related to a lactic acid bacteria strain composition and its application for improving chronic kidney disease. The technical problem to be solved by the present invention is to provide a microbial composition, which has the effect of reducing uremic toxins and their precursors and slowing down renal tissue lesions to improve chronic kidney disease (chronic kidney disease, CKD) and improve renal function. The technical scheme of the present invention is a lactic acid bacteria strain pharmaceutical composition for improving chronic kidney disease, which includes a lactic acid bacteria strain mixture and a pharmaceutically acceptable carrier; the lactic acid bacteria strain mixture includes Lactobacillus acidophilus (Lactobacillus acidophilus) PCo-96, Lactobacillus casei (Lacticaseibacillus casei) ZE-2, Bifidobacterium longum subsp. infantis (Bifidobacterium longum subsp. infanttis) BR631 and Streptococcus salivarius subsp. thermophilus (Streptococcus salivarius subsp. thermophilus) Hot-06. The lactic acid bacteria strain composition of the present invention provides a new option for improving chronic kidney disease or maintaining renal function.
Owner:BIO RACE BIOTECH HANGZHOU CO LTD

Application of miR-152 as a target in preparation of a drug for treating podocytopathy and the drug

The application belongs to the field of biological medicine, and provides application of miR-152 as a target in preparation of a drug for treating podocytopathy and the drug. Specifically, the application relates to application of miR-152 as a therapeutic target and / or a drug screening target in preparation of a drug for treating podocytopathy and a drug for treating FSGS nephropathy. The miR-152 inhibitor can inhibit high expression of miR-152 in kidney tissues of podocytopathy or FSGS nephropathy, inhibit down-regulation of synaptopodin protein, RhoA protein and 14-3-3 beta protein expression, protect stability of a cytoskeleton of a podocyte in kidney tissues, and delay progressive development of FSGS disease. The application provides a new therapeutic target for treatment of FSGS disease, and has important social and economic significance.
Owner:张学明

Application of substances that inhibit CAPG activity in preparing products for treating renal fibrosis caused by renal injury

The present invention belongs to the field of biomedical technology and specifically discloses the use of a substance that inhibits the activity and / or expression of a CAPG gene or protein in preparing a product for treating renal fibrosis caused by renal injury. The present invention first discovered through research that CAPG is expressed at a low level in normal renal tissue, but its expression level is elevated in renal tissue of patients with acute renal injury, minimal change disease, IgA nephropathy, lupus nephritis, and diabetic nephropathy, indicating that CAPG expression may be involved in the occurrence and development of renal fibrosis caused by renal injury. Then, by constructing a CAPG knockout mouse model, it was found that knocking out CAPG can effectively reduce the progression of renal fibrosis. By culturing renal fibroblasts in vitro, it was found that silencing or knocking down CAPG can inhibit TGF-β-induced renal fibroblast activation. The research of the present invention is of great significance for the pathogenesis and treatment of renal injury or renal fibrosis.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Compound for inhibiting c3 gene expression, pharmaceutical composition and use thereof

A compound for inhibiting C3 gene expression, a pharmaceutical composition and a use thereof, belonging to the technical field of small nucleic acid drug delivery. A compound conjugated with an oligonucleotide and a pharmaceutical composition thereof can significantly inhibit the expression of C3 mRNA in animal liver tissue and C3 protein in serum and can reduce C3 deposition in renal tissue and improve the course of disease featuring C3 deposition in renal tissue. The no-adverse-effect level (NOAEL) in SD rats and cynomolgus monkeys is 300 mg / kg. The compound conjugated with a oligonucleotide and the pharmaceutical composition thereof are helpful in alleviating, preventing and / or treating diseases or conditions mediated by dysregulated C3 gene expression.
Owner:RIGERNA THERAPEUTICS (SUZHOU) CO LTD

A traditional Chinese medicine composition for treating diabetic nephropathy and its preparation method

The present invention relates to a traditional Chinese medicine composition for treating diabetic nephropathy and a preparation method thereof, belonging to the technical field of traditional Chinese medicine compositions. To solve the problems of single target for western medicine in treating diabetic nephropathy and high risk of adverse reactions when using a combination of multiple drugs, the present invention provides a traditional Chinese medicine composition for treating diabetic nephropathy. The composition formula includes white ginseng, astragalus membranaceus, stir-fried atractylodes macrocephala, poria cocos, chicken gizzard-membrane, kudzu root, wolfberry fruit, Chinese yam, cornel fruit and oriental waterplantain rhizome. The traditional Chinese medicine composition of the present invention has the advantages of multiple components and multiple targets and small adverse reactions. Animal experiments prove that the traditional Chinese medicine composition provided by the present invention can significantly improve the blood glucose, blood lipid, urine protein, creatinine and blood urea nitrogen levels of rats, can significantly improve the pathological changes of the renal tissue of model rats, and can correct the podocyte metabolic pathway and restore its mitochondrial function by specifically increasing the activities of SIRT1 and PGC-1α. It is an effective medicine for treating diabetic nephropathy and provides a new way for the multi-target treatment of clinical diabetic nephropathy.
Owner:HEILONGJIANG UNIV OF CHINESE MEDICINE

Use of quinolinic acid in the preparation of drugs for preventing and treating acute kidney injury

This invention discloses the application of quinolinic acid in the preparation of drugs for the prevention and treatment of acute kidney injury (AKI). AKI refers to acute kidney injury induced by renal ischemia-reperfusion. The drug is an oral formulation used for prophylactic administration in high-risk individuals undergoing iatrogenic procedures at potential AKI risk, and for pretreatment of ischemic conditions in transplanted kidneys. Experiments have shown that administration of quinolinic acid significantly reduces serum urea nitrogen levels in AKI mice, alleviates renal tissue morphological damage in AKI mice, and reduces the expression level of the renal tubular injury factor NGAL protein in AKI mice, demonstrating significant clinical value in the prevention and treatment of AKI.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

Kidney-targeting delivery ligand, conjugate, composition and use thereof

PCT designated stageWO2025228157A1PeptidesUrinary disorderRenal tissueNucleotide
Provided are a kidney-targeting delivery ligand, a conjugate, a composition, and a use thereof, relating to the technical field of oligonucleotide drugs. Provided is a delivery ligand suitable for kidney targeting. The delivery ligand and an active substance (such as an oligonucleotide) are covalently linked by means of a linker group to obtain an oligonucleotide conjugate. The oligonucleotide conjugate has affinity for a cell receptor present on a kidney target cell and can selectively and effectively reduce or inhibit the expression of a kidney target gene in a subject (such as human or animal). The provided oligonucleotide conjugate or pharmaceutical composition can effectively treat and / or prevent pathological conditions or diseases caused by aberrant expression of a specific gene in kidney tissue cells.
Owner:RIGERNA THERAPEUTICS (BEIJING) CO LTD

A kind of inulin fermentation product for reducing blood sugar and its preparation and application

The present invention provides a blood sugar lowering inulin fermentation product and its preparation and application, belonging to the field of microbial fermentation technology. The blood sugar lowering inulin fermentation product is obtained by fermenting inulin with a specific fermentation bacterium, Schleiferilactobacillus harbinensis JNDM, which has been deposited in the Guangdong Provincial Microbiological Culture Collection Center on December 11, 2023, with a deposit number of GDMCC No. 64143. The inulin fermentation product can significantly enhance the blood sugar lowering effect of inulin, reduce complications of hyperglycemia, improve anti-inflammatory function, and effectively relieve pancreatic and renal tissue lesions; it can regulate the homeostasis of intestinal flora, and significantly increase the diversity of intestinal microorganisms and the content of beneficial metabolites in the intestine. It can be used as a food, health product, medicine or functional beverage for preventing and treating type 2 diabetes and its complications or for lowering blood sugar.
Owner:CHANGZHOU WANHE BIOTECHNOLOGY CO LTD

Application of trigonelline in preparation of medicine for treating sepsis

The invention provides application of trigonelline in preparation of a medicine for treating sepsis, and belongs to the technical field of biological medicine. The invention develops a novel medicine, namely the trigonelline for treating sepsis, the treatment effect of the trigonelline on sepsis is detected, and the result proves that the treatment of the trigonelline can inhibit kidney tissue injury caused by sepsis and reduce the expression of inflammatory factors. The natural chemical component trigonelline extracted from plants is used for treating sepsis injury, the safety is high, the treatment effect is good, a new effective treatment medicine is provided for treatment of sepsis, and the problem that an effective sepsis prevention and treatment medicine is lacked clinically is solved.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

15-antibody combination for accurately detecting mouse tissue immune cell subsets and application of 15-antibody combination

The invention discloses a 15-antibody combination for accurately detecting a mouse tissue immune cell subset and application of the 15-antibody combination. Aiming at the problems of large fluctuation and instability of detection results caused by adjustment of voltage and fluorescence compensation during detection by a flow cytometer and different processing modes during result analysis, the antibody combination disclosed by the invention takes monoclonal antibodies CD45, CD3, CD4, CD8, CD19, B220, Ly-6C, Ly-6G, MHC-II, CD11c, CD49b, CD62L, CD44 +, PD-1 and PD-L1 as effective components, and a stable and standard detection method for mouse tissue immune cell subsets is established. The method can analyze the proportion, number and distribution of various immune cells (T cells, B cells, NK cells, dendritic cells, mononuclear cells and granulocytes) in spleen, lung, liver, brain or kidney tissues of mice, can reflect the immune state of the mice and evaluate the immunosuppression state, and can be applied to the fields of disease models, drug evaluation, vaccine development and the like.
Owner:ZHEJIANG UNIV